pmc logo imageJournal ListSearchpmc logo image
Logo of nuclrecBioMed Central web siteReference to the article.Search.Manuscript submission.Registration.Journal front page.
Nucl Recept. 2007; 5: 1.
Published online 2007 May 25. doi: 10.1186/1478-1336-5-1.
PMCID: PMC1899481
The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance
Alistair VW Nunn,corresponding author1 Jimmy Bell,1 and Philip Barter2
1Molecular Imaging Group, Medical Research Council Clinical Sciences Centre, Imperial College, Hammersmith Campus, London W12 0HS, UK
2The Heart Research Institute, Camperdown, Sydney, NSW 2050, Australia
corresponding authorCorresponding author.
Alistair VW Nunn: alistair.nunn/at/btconnect.com; Jimmy Bell: jimmy.bell/at/csc.mrc.ac.uk; Philip Barter: p.barter/at/hri.org.au
Received October 17, 2006; Accepted May 25, 2007.
Abstract
The peroxisomal proliferating-activated receptors (PPARs) are lipid-sensing transcription factors that have a role in embryonic development, but are primarily known for modulating energy metabolism, lipid storage, and transport, as well as inflammation and wound healing. Currently, there is no consensus as to the overall combined function of PPARs and why they evolved. We hypothesize that the PPARs had to evolve to integrate lipid storage and burning with the ability to reduce oxidative stress, as energy storage is essential for survival and resistance to injury/infection, but the latter increases oxidative stress and may reduce median survival (functional longevity). In a sense, PPARs may be an evolutionary solution to something we call the 'hypoxia-lipid' conundrum, where the ability to store and burn fat is essential for survival, but is a 'double-edged sword', as fats are potentially highly toxic. Ways in which PPARs may reduce oxidative stress involve modulation of mitochondrial uncoupling protein (UCP) expression (thus reducing reactive oxygen species, ROS), optimising forkhead box class O factor (FOXO) activity (by improving whole body insulin sensitivity) and suppressing NFkB (at the transcriptional level). In light of this, we therefore postulate that inflammation-induced PPAR downregulation engenders many of the signs and symptoms of the metabolic syndrome, which shares many features with the acute phase response (APR) and is the opposite of the phenotype associated with calorie restriction and high FOXO activity. In genetically susceptible individuals (displaying the naturally mildly insulin resistant 'thrifty genotype'), suboptimal PPAR activity may follow an exaggerated but natural adipose tissue-related inflammatory signal induced by excessive calories and reduced physical activity, which normally couples energy storage with the ability to mount an immune response. This is further worsened when pancreatic decompensation occurs, resulting in gluco-oxidative stress and lipotoxicity, increased inflammatory insulin resistance and oxidative stress. Reactivating PPARs may restore a metabolic balance and help to adapt the phenotype to a modern lifestyle.